I favor therapy for hepatitis C virus recurrence after transplantation

Liver Transplantation

Volumn 8, Issue 10 SUPPL. 1, 2002, Pages s55-s58

  Samuel, Didier ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ACUTE DISEASE; ALLOGRAFT; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE COURSE; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; GRAFT REJECTION; GRAFT SURVIVAL; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; REINFECTION; VIRUS LOAD;

EID: 0036794607     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.35857     Document Type: Article

References (32)

1. European Liver Transplant Registry- ELTR. Registry for the European Liver Transplant Association, data analysis, 05/1968-12/2000. Available at: http://www-eltr.vjf.inserm.fr. Accessed:December 2001.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122: 889-896.
3. Wright TL, Donegan E, Hsu H, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322.
4. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334: 815-820.
5. Feray C, Gigou M, Samuel D, David MF, Paradis V, Reynes M, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994;20:1137-1143.
6. Feray C, Caccamo L, Alexander GJM, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999;117:619-625.
7. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999;29:250-256.
8. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
9. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-687.
10. Samuel D, Feray C. Recurrence of hepatitis C virus after liver transplantation. J Hepatol 1999;31(suppl 1):S217-S221.
11. Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, et al. Interferon alfa for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial. Transplantation 1998;65:82-86.
12. Sheiner PA, Boros P, Klion FM, Thung SN, Schluger LK, Lau JYN, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831-838.
13. Mazzafero V, Regalia E, Pulvirenti A, Tagger A, Andreola S, Pasquali M, et al. Prophylaxis against HCV recurrence after liver transplantation. Effect of interferon and ribavirin combination. Transplant Proc 1997;29:519-521.
14. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673-684.
15. Berenguer M, Wright TL. Recurrence of hepatitis C after liver transplantation. J Hepatol 2001:35:666-678.
16. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852-858.
17. Wright TL, Combs C, Kim M, Ferrell L, Bacchetti P, Ascher N, et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994;20:773-779.
18. Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995;22:1084-1089.
19. Gane EJ, Lo SK, Riordan SM, Portmann BC, Lau JYN, Naoumov NV, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998;27:1403-1407.
20. Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994;330:1160-1161.
21. Gaidano AC, Mosnier JF, Durand F, Martinot-Peignoux M, Marcellin P, Degott C, et al. Alpha-interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen. Transplantation 1995;59: 1627-1629.
22. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliot M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997;26:500-504.
23. Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001;7:181-190.
24. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil A. Recurrent hepatitis C after liver transplantation: A nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001;10:863-869.
25. Alberti A, Belli L, Airoldi A, De Carlis L, Rondinara G, Minola E, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study. Liver Transpl 2001;10:870-876.
26. Lavezzo B, Franchello A, Smedile A, David E, Barbuz A, Torrani M, et al. Treatment of recurrent hepatitis C in liver transplants: Efficacy of a six versus a twelve month course of interferon alpha 2b with ribavirin. J Hepatol 2002;37:247-252.
27. De Vera M, Smallwood G, Rosado K, Davis L, Martinez E, Sharma S, et al. Interferon alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001;71:678-686.
28. Samuel D, Bizollon T, Feray C, Roche B, Si Ahmed SN, Lemonnier C, et al. Combination of interferon alfa 2b plus ribavirin for recurrent HCV infection after liver transplantation: A randomized controlled study [abstract]. Hepatology 2000;32:295A.
29. Haeckel E, Kornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alpha-2b. N Engl J Med 2001;345:1452-1457.
30. Di Martino V, Saurini F, Samuel D, Gigou M, Dussaix E, Reynes M, et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997;26:1343-1350.
31. Bizollon T, Trepo C. Ribavirin and interferon combination for recurrent hepatitis C: Which benefit beyond 6 months? J Hepatol 2002;37:274-276.
32. The French Metavir Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.